Cargando…
How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
BACKGROUND: For localized prostate cancer (PCa), radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality. Contemporary studies contained the elderly people; analyses focusing on patients over 75 years of age were still lacking. METHOD: In the Surveil...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601593/ https://www.ncbi.nlm.nih.gov/pubmed/31066510 http://dx.doi.org/10.1002/cam4.2221 |
_version_ | 1783431317968388096 |
---|---|
author | Jin, Kun Qiu, Shi Li, Jiakun Zheng, Xiaonan Tu, Xiang Liao, Xinyang Yang, Yan Yang, Lu Wei, Qiang |
author_facet | Jin, Kun Qiu, Shi Li, Jiakun Zheng, Xiaonan Tu, Xiang Liao, Xinyang Yang, Yan Yang, Lu Wei, Qiang |
author_sort | Jin, Kun |
collection | PubMed |
description | BACKGROUND: For localized prostate cancer (PCa), radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality. Contemporary studies contained the elderly people; analyses focusing on patients over 75 years of age were still lacking. METHOD: In the Surveillance Epidemiology and End Results (SEER) database (2004‐2015), people over 75 years of age with cT2 stage were selected in our research. Multivariable Cox proportional hazard models were used to analyze cancer‐specific mortality (CSM) and overall mortality (OM) after adjustment. The propensity score matching was performed to assume the randomization. An instrument variate (IVA) was used to calculate the unmeasured confounders. RESULTS: Radical prostatectomy is superior to RT in OM and CSM after adjustment for covariates (HR = 0.54, 95% CI = 0.47‐0.62, P < 0.001 and HR = 0.30, 95% CI = 0.20‐0.45, P < 0.001, respectively). The cox model after matching indicated similar consequence (OM: HR = 0.53, 95% CI = 0.46‐0.62, P < 0.001; CSM: HR = 0.27, 95% CI = 0.17‐0.43, P < 0.001). In the IVA‐adjusted model, the effect of treatment changed slightly (OM: HR = 0.65, 95% CI = 0.54‐0.78, P < 0.001; CSM: HR = 0.21, 95% CI = 0.12‐0.37, P < 0.001). Subgroup analyses showed that for patients with GS = 7, those received RP obtained the highest risk decline for overall death (HR = 0.41, 95% CI = 0.32‐0.52); and for patients with younger age, those received RP obtained the highest risk decline for CSM (HR = 0.11, 95% CI = 0.01‐0.52). CONCLUSION: Patients over 75 years of age with cT2 stage will obtain more benefit from RP compared with RT, especially for patients with GS = 7 and younger age. |
format | Online Article Text |
id | pubmed-6601593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66015932019-07-22 How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? Jin, Kun Qiu, Shi Li, Jiakun Zheng, Xiaonan Tu, Xiang Liao, Xinyang Yang, Yan Yang, Lu Wei, Qiang Cancer Med Clinical Cancer Research BACKGROUND: For localized prostate cancer (PCa), radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality. Contemporary studies contained the elderly people; analyses focusing on patients over 75 years of age were still lacking. METHOD: In the Surveillance Epidemiology and End Results (SEER) database (2004‐2015), people over 75 years of age with cT2 stage were selected in our research. Multivariable Cox proportional hazard models were used to analyze cancer‐specific mortality (CSM) and overall mortality (OM) after adjustment. The propensity score matching was performed to assume the randomization. An instrument variate (IVA) was used to calculate the unmeasured confounders. RESULTS: Radical prostatectomy is superior to RT in OM and CSM after adjustment for covariates (HR = 0.54, 95% CI = 0.47‐0.62, P < 0.001 and HR = 0.30, 95% CI = 0.20‐0.45, P < 0.001, respectively). The cox model after matching indicated similar consequence (OM: HR = 0.53, 95% CI = 0.46‐0.62, P < 0.001; CSM: HR = 0.27, 95% CI = 0.17‐0.43, P < 0.001). In the IVA‐adjusted model, the effect of treatment changed slightly (OM: HR = 0.65, 95% CI = 0.54‐0.78, P < 0.001; CSM: HR = 0.21, 95% CI = 0.12‐0.37, P < 0.001). Subgroup analyses showed that for patients with GS = 7, those received RP obtained the highest risk decline for overall death (HR = 0.41, 95% CI = 0.32‐0.52); and for patients with younger age, those received RP obtained the highest risk decline for CSM (HR = 0.11, 95% CI = 0.01‐0.52). CONCLUSION: Patients over 75 years of age with cT2 stage will obtain more benefit from RP compared with RT, especially for patients with GS = 7 and younger age. John Wiley and Sons Inc. 2019-05-08 /pmc/articles/PMC6601593/ /pubmed/31066510 http://dx.doi.org/10.1002/cam4.2221 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Jin, Kun Qiu, Shi Li, Jiakun Zheng, Xiaonan Tu, Xiang Liao, Xinyang Yang, Yan Yang, Lu Wei, Qiang How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? |
title | How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? |
title_full | How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? |
title_fullStr | How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? |
title_full_unstemmed | How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? |
title_short | How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? |
title_sort | how to choose proper local treatment in men aged ≥75 years with ct2 localized prostate cancer? |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601593/ https://www.ncbi.nlm.nih.gov/pubmed/31066510 http://dx.doi.org/10.1002/cam4.2221 |
work_keys_str_mv | AT jinkun howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT qiushi howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT lijiakun howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT zhengxiaonan howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT tuxiang howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT liaoxinyang howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT yangyan howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT yanglu howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer AT weiqiang howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer |